Molecular and immune mechanisms in the pathogenesis of cardiomyopathy - Role of viruses, cytokines, and nitric oxide

Japanese Circulation Journal

Volumn 61, Issue 4, 1997, Pages 275-291

  Matsumori, Akira ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Cardiomyopathy; Cytokine; Heart failure; Myocarditis; Virus

Indexed keywords

AMRINONE; CYTOKINE; NITRIC OXIDE; PIMOBENDAN; PIPERANOMETOZINE;

ADOLESCENT; ADULT; AGED; ANTIGEN RECOGNITION; CARDIOMYOPATHY; CELL DAMAGE; CLINICAL ARTICLE; ENZYME INDUCTION; FEMALE; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HUMAN; MALE; MOLECULAR BIOLOGY; PATHOGENESIS; POLYMERASE CHAIN REACTION; REVIEW; VIRUS MYOCARDITIS;

ANIMALS; CARDIOMYOPATHIES; CARDIOMYOPATHY, DILATED; CARDIOMYOPATHY, HYPERTROPHIC; CYTOKINES; HEPATITIS C; HUMANS; MYOCARDITIS; NITRIC OXIDE;

EID: 0030940734     PISSN: 00471828     EISSN: None     Source Type: Journal    
DOI: 10.1253/jcj.61.275     Document Type: Review

References (104)

1. Kawai C, Matsumori A, Fujiwara H: Myocarditis and dilated cardiomyopathy. Annu Rev Med 1987; 38: 221-239
2. Abelmann WH, Lorell BH: The challenge of cardiomyopathy. J Am Coll Cardiol 1989; 13: 1219-1239
3. Olinde KD, O'Connell JB: Inflammatory heart disease: pathogenesis, clinical manifestations, and treatment of myocarditis. Annu Rev Med 1994; 45: 481-490
4. Caforio ALP, Stewart JT, McKenna WJ: Idiopathic dilated cardiomyopathy. Br Med J 1990; 300: 890-891
5. Johnson RA, Palacios I: Dilated cardiomyopathies of the adult (second of 2 parts). N Engl J Med 1982; 307: 1119-1126
6. Matsumori A, Kawai C: An experimental model for congestive heart failure after encephalomyocarditis virus myocarditis in mice. Circulation 1982; 65: 1230-1235
7. Matsumori A, Kawai C: An animal model of congestive (dilated) cardiomyopathy: dilatation and hypertrophy of the heart in the chronic stage in DBA/2 mice with myocarditis caused by encephalomyocarditis virus. Circulation 1982; 66: 377-380
8. Matsumori A: Animal models: pathological findings and therapeutic considerations. In: Banatvala JE, editor. Viral infection of the heart. London: Edward Arnold, 1993; 110-137
9. Kawano H, Kawai S, Nishijo T, Shirai T, Inagaki Y, Okada R: An autopsy case of hypertrophic cardiomyopathy with pathological findings suggesting chronic myocarditis. Jpn Heart J 1994; 35: 95-105
10. Kyu B, Matsumori A, Sato Y, Okada I, Chapman NM, Tracy S: Cardiac persistence of cardioviral RNA detected by the polymerase chain reaction in a murine model of dilated cardiomyopathy. Circulation 1992; 86: 522-530
11. Why HJF, Meany BT, Richardson PJ, Olsen EGJ, Bowles NE, Cunningham L, et al: Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy. Circulation 1994; 89: 2582-2589
12. Giacca M, Severini GM, Mestroni L, Salvi A, Lardieri G, Falaschi A, et al: Low frequency of detection by nested polymerase chain reaction of enterovirus ribonucleic acid in endomyocardial tissue of patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994; 24: 1033-1040
13. Martin AB, Webber S, Fricker FJ, Jaffe R, Demmler G, Kearny D, et al: Acute myocarditis. Rapid diagnosis by PCR in children. Circulation 1994; 90: 330-339
14. Matsumori A, Matoba Y, Sasayama S: Dilated cardiomyopathy associated with hepatitis C virus infection. Circulation 1995; 92: 2519-2525
15. Aria KTN, Sallie R, Sangar D, Alexander GJM, Smith H, Byrne J, et al: Detection of genomic and intermediate replicative strands of hepatitis C virus in liver tissue by in situ hybridization. J Clin Invest 1993; 91: 2226-2234
16. Matsumori A, Matoba Y, Nishio R, Shioi T, Ono K, Sasayama S: Detection of hepatitis C virus RNA from the heart of patients with hypertrophic cardiomyopathy. Biochem Biophys Res Commun 1996; 222: 678-682
17. Oppenheim, JJ, Saklatvala J: Cytokine and their receptors. In: Oppenheim JJ, Rossio JL, Gearing AJH, editors. Clinical Applications of Cytokine. Role in pathogenesis, Diagnosis, and Therapy. Oxford: Oxford University Press, 1993; 3-15
18. Levine B, Kalman J, Mayer L, Fillit HM, Packer M: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323: 236-241
19. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S: Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 1994; 72: 561-566
20. Katz SD, Rao R, Berman JW, et al: Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure; Relation to nitric oxide-dependent vasodilation in the forearm circulation. Circulation 1994; 90: 12-16
21. Torre-Amione G, Kapadia S, Lee J, Bies RD, Lebovitz R, Mann DL: Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 1995; 92: 1487-1493
22. Latini R, Bianchi M, Correale E, et al: Cytokine in acute myocardial infarction: Selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin-1 receptor antagonist. J Cardiovasc Pharmacol 1994; 23: 1-6
23. Kapadia S, Torre-Amione G, Yokoyama T, Mann DL: Soluble TNF binding proteins modulate the negative inotropic properties TNF-α in vitro. Am J Physiol 1995; 268: H517-H525
24. Ferrari R, Bachetti T, Confortini R, et al: Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995; 92: 1479-1486
25. Packer M: Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure? Circulation 1995; 92: 1379-1382
26. Limas CJ, Goldenberg IF, Limas C: Soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy. Correlation with disease severity and cardiac autoantibodies. Circulation 1995; 91: 631-634
27. Miyao Y, Yasue H, Ogawa H, et al: Elevated plasma interleukin-6 levels in patients with acute myocardial infarction. Am Heart J 1993; 126: 1299-1304
28. Neumann F-J, Ott I, Gawaz M, et al: Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation 1995; 92: 748-755
29. Kanda T, Hirao Y, Oshima S, et al: Interleukin-8 as a sensitive marker of unstable coronary artery disease. Am J Cardiol 1996; 77: 304-307
30. Kukielka GL, Smith CW, LaRosa GJ, et al: Interleukin-8 gene induction in the myocardium after ischemia and reperfusion in vivo. J Clin Invest 1995; 95: 89-103
31. Matsumori A, Furukawa Y, Hashimoto T, Yoshida A, Ono K, Shioi T, et al: Plasma levels of the monocyte chemotactic and activating factor/monocyte chemotactic protein-1 are elevated in patients with acute myocardial infarction. J Mol Cell Cardiol 1997; 29: 419-423
32. Ghezzi P, Dinarello CA, Bianchi M, Rosandich ME, Repine JE, White CW: Hypoxia increases production of interleukin-1 and tumor necrosis factor by human mononuclear cells. Cytokine 1991; 3: 189-194
33. Yamauchi-Takihara K, Ihara Y, Ogata A, Yoshizaki K, Azuma J, Kishimoto T: Hypoxic stress induces cardiac myocyte-derived interleukin-6. Circulation 1995; 91: 1520-1524
34. Kapadia S, Lee J, Torre-Amione G, Birdsall HH, Ma TS, Mann DL: Tumor necrosis factor-α gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest 1995: 96: 1042-1052
35. Tsujino M, Hirata Y, Imai T, et al: Induction of nitric oxide synthase gene by interleukin-1β in cultured rat cardiocytes. Circulation 1994; 90: 375-383
36. Balligand J-L, Ungureanu D, Kelly RA, Pimentai D, Michel T, Smith TW: Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium. J Clin Invest 1993; 91: 2314-2319
37. Evans HG, Lewis MJ, Shar AM: Interleukin-1β modulates myocardial contraction via dexamethasone-sensitive production of nitric oxide. Cardiovasc Res 1993; 27: 1486-1490
38. i and cell contraction in cultured chick ventricular myocytes. Circ Res 1994; 75: 285-295
39. Hosenpud JD, Campbell SM, Mendelson DJ: Interleukin-1 induced myocardial depression in an isolated beating heart preparation. J Heart Transplant 1989; 8: 460-468
40. Weisensee D, Bereiter-Hahn J, Schoeppe W, Friedrich LW: Effects of cytokines on the contractility of cultured cardiac myocytes. Int J Immunopharmacol 1993; 15: 581-587
41. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL: Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992; 257: 387-389
42. Li Y-H, Rozanski GJ: Effects of human recombinant interleukin-1 on electrical properties of guinea pig ventricular cells. Cardiovasc Res 1993; 27: 525-530
43. 2+ current by interleukin-1β in cultured rat ventricular myocytes. Am J Physiol 1995; 268: C339-C349
44. Libby P, Wamer SJ, Friedman GB: Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoid. J Clin Invest 1988; 81: 487-498
45. Boluyt MO, O'Neill L, Meredith AL, et al: Alternation in cardiac gene expression during the transition from stable hypertrophy to heart failure: marked upregulation of genes encoding extracellular matrix components. Circ Res 1994; 75: 23-32
46. Pinsky DJ, Cai B, Yang X, Rodriguez C, Sciacca RR, Cannon PJ: The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor β. J Clin Invest 1995; 95: 677-685
47. Woodley SL, McMillan M, Shelby J, et al: Myocyte injury and contraction abnormalities produced by cytotoxic T lymphocytes. Circulation 1991; 83: 1410-1418
48. Seko Y, Ishiyama S, Nishikawa T, et al: Restricted usage of T cell receptor Vα-Vβ genes in infiltrating cells in the hearts of patients with acute myocarditis and dilated cardiomyopathy. J Clin Invest 1995; 96: 1035-1041
49. Thaik CM, Calderone A, Takahashi N, Colucci WS: Interleukin-1β modulates the growth and phenotype of neonatal rat cardiac myocytes. J Clin Invest 1995; 96: 1093-1099
50. Beck AC, Ward JH, Hammond EH, Wray RB, Samlowski WE: Cardiomyopathy associated with high-dose interleukin-2 (IL-2) therapy. West J Med 1991; 158: 293-296
51. Sobotka PA, McMannis J, Fisher RI, Stein DG, Thomas JX Jr: Effects of interleukin 2 on cardiac function in the isolated rat heart. J Clin Invest 1990; 86: 845-850
52. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL: Cellular basis for the negative inotropic effects of tumor necrosis factor-α in the adult mammalian heart. J Clin Invest 1993; 92: 2303-2312
53. Ungureanu-Longrois D, Balligand J-L, Simmons WW, Okada I, Kobzik L, Lowenstein CJ. et al: Induction of nitric oxide synthase activity by cytokines in ventricular myocytes is necessary but not sufficient to decrease contractile responsiveness to β-adrenergic agonists. Circ Res 1995; 77: 494-502
54. Balligand J-L, Ungureanu-Longrois D, Simmons WW, et al: Cytokine-inducible nitric oxide synthase (iNOS) expression in cardiac myocytes. J Biol Chem 1994; 269: 27580-27588
55. Shindo T, Ikeda U, Ohkawa F, Kawahara Y, Yokoyama M, Shimada K: Nitric oxide synthesis in cardiac myocytes and fibroblasts by inflammatory cytokines. Cardiovasc Res 1995; 29: 813-819
56. Ungureanu-Longrois D, Balligand J-L, Okada I, et al: Contractile responsiveness of ventricular myocytes to isoproterenol is regulated by induction of nitric oxide synthase activity in cardiac microvascular endothelial cells in heterotypic primary culture. Circ Res 1995; 77: 486-493
57. Schulz R, Panas DL, Catena R, Moncada S, Olley PM, Lopaschuck GD: The role of nitric oxide in cardiac depression induced by interleukin-1β and tumor necrosis factor-α. Br J Pharmacol 1995; 114: 27-34
58. Hirota H, Yoshida K, Kishimoto T, Taga T: Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci USA 1995; 92: 4862-4866
59. Mann DL, Young JB: Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. Chest 1994; 105: 897-904
60. Wei X-Q, Charles IG, Smith A, et al: Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 1995; 375: 408-411
61. Matsumori A, Yamada T, Kawai C: Immunomodulating therapy in viral myocarditis: effects of tumor necrosis factor, interleukin 2 and anti-interleukin-2 receptor antibody in an animal model. Eur Heart J 1991; 12(Suppl D): 203-205
62. Yamada T, Matsumori A, Sasayama S: Therapeutic effects of anti-tumor necrosis factor-α antibody on the murine model of viral myocarditis induced by encephalomyocarditis virus. Circulation 1994; 89: 846-851
63. Shioi T, Matsumori A, Sasayama S: Persistent expression of cytokine in the chronic stage of viral myocarditis in mice. Circulation 1996; 94: 2930-2937
64. Jaattela M: Biology of disease: biologic activities and mechanisms of action of tumor necrosis factor-alpha/cachectin. Lab Invest 1991; 64: 724-742
65. Taniguchi T: Regulation of cytokine gene expression. Annu Rev Immunol 1988; 6: 439-464
66. Efrat S, Pilo S, Kaempfer R: Kinetics of induction and molecular size of mRNAs encoding human interleukin-2 and gamma-interferon. Nature 1982; 297: 236-239
67. Kodama M, Hanawa H, Saeki M, et al: Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. Circ Res 1994; 75: 278-284
68. Sasasayama S: What do the newer inotropic drugs have to offer? Cardiovasc Drugs Therapy 1992; 6: 15-18
69. Feldman AM, Bristow MR, Parmley WW, et al: Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993; 329: 149-155
70. Matsui S, Matsumori A, Matoba Y, Uchida A, Sasayama S: Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone: suppression of natural killer cell activity and tumor necrosis factor-α production. J Clin Invest 1994; 94: 1212-1217
71. Shioi T, Matsumori A, Matsui S, Sasayama S: Inhibition of cytokine production by a new inotropic agent, vesnarinone, in human lymphocytes, T cell line, and monocytic cell line. Life Sci 1994; 54: PL11-16
72. Matsumori A, Shioi T, Yamada T, Matsui S, Sasayama S: Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation 1994; 89: 955-958
73. Sato Y, Matsumori A, Sasayama S: Inotropic agent vesnarinone inhibits cytokine production and E-selectin expression in human umbilical vein endothelial cells. J Mol Cell Cardiol 1995; 27: 2265-2273
74. Matsui S, Matsumori A, Sasayama S: Vesnarinone prolongs survival and reduces lethality in a murine model of lethal endotoxemia. Life Sci 1994; 55: 1735-1741
75. Matsumori A, Ono K, Sato Y, Shioi T, Nose Y, Sasayama S: Differential modulation of cytokine production by drugs: Implication for therapy in heart failure. J Mol Cell Cardiol 1996; 28: 2491-2499
76. Hurme M: Modulation of interleukin-1β production by cyclic AMP in human monocytes. FEBS Lett 1990; 263: 35-37
77. Serkkola E, Hurme M, Palkama T: Prolonged elevation of intracellular cyclic AMP activated interleukin-1 production of human peripheral blood monocytes. Scand J Immunol 1992; 35: 203-208
78. Katz AM: The cardiomyopathy of overload: an unnatural growth response in the hypertrophied heart. Ann Int Med 1994; 121: 363-371
79. Molnar-Kimber K, Yonno L, Heaslip R, Weichman B: Modulation of TNF-α and IL-1β from endotoxin-stimulated monocytes by selective PDE isozyme inhibitors. Agents Actions 1993; 39: C77-C79
80. 2 and cyclic GMP. Immunobiology 1990; 182: 44-55
81. Essayan DM, Huang S-K, Undem BJ, Kagey-Sobotka A, Lichtenstein LM: Modulation of antigen- and mitogen-induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J Immunol 1994; 153: 3408-341
82. Gallin EK: Ion channels in leukocytes. Pharmacol Rev 1991; 71: 775-811
83. Lewis RS, Cahalan MD: Ion channels and signal transduction in lymphocytes. Annu Rev Physiol 1990; 52: 415-430
84. + channels depolarize human T lymphocytes: mechanism of antiproliferative effect of charybdotoxin. Proc Natl Acad Sci USA 1992; 89: 10094-10098
85. + currents in cytotoxic T lymphocytes. Circ Res 1996; 78: 253-261
86. Iijima T, Taira N: Membrane current changes responsible for the positive inotropic effect of OPC 8212, a new positive inotropic agent, in single cells of the guinea pig heart. J Pharmacol Exp Ther 1987; 240: 657-662
87. Winlaw DS, Smythe GA, Keogh AM, Schyvens CC, Spratt PM, MacDonald PS: Nitric oxide production and heart failure. Lancet 1994; 344: 373-374
88. De Beider AJ, Radomski MW, Why HJF, et al: Nitric oxide synthase activities in human myocardium. Lancet 1993; 341: 84-85
89. Hattori Y, So S, Hattori S, Kasai K, Shimada S: Vesnarinone inhibits induction of nitric oxide synthase in J774 macrophages and rat cardiac myocytes in culture. Cardiovasc Res 1995; 30: 187-192
90. Matsumori A, Okada I, Shioi T, et al: Inotropic agents differentially inhibit the induction of nitric oxide synthase by endotoxin in cultured macrophages. Life Sci 1996; 59: PL121-PL125
91. Kubo SH, Gollub S, Bourge R, et al: Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Circulation 1992; 85: 942-949
92. Koh WS, Yang K-H, Kaminski NE: Cyclic AMP is an essential factor in immune responses. Biochem Biophys Res Commun 1995; 206: 703-709
93. Auwerx L, Sassone-Corsi P: IP-1: a dominant inhibitor of Fos/Jun whose activity is modulated by phosphorylation. Cell 1991; 64: 989-993
94. Park DJ, Min HK, Rhee SG: Inhibition of CD3-linked phospholipase C by phorbol ester and by cAMP is associated with decreased phosphotyrosine and increased phosphoserine contents of PLC-gamma 1. J Biol Chem 1992; 267: 1496-1501
95. Packer M, Nicod P, Khandheria BR, et al: Randomized, multicenter, double-blind, placebo-controlled evaluation of amlodipine in patients with mild-to-moderate heart failure. J Am Coll Cardiol 1991; 17(Suppl): 274A
96. Packer M, O'Connor CM, Ghali JK, et al: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996; 335: 1107-1114
97. Wang W, Matsumori A, Yamada T, et al: Beneficial effects of amlodipine in a murine model of congestive heart failure induced by viral myocarditis: a possible mechanism through inhibition of nitric oxide production. Circulation 1997; 95: 245-251
98. Dong R, Liu P, Wee L, Vutany J, Sole MJ: Verapamil ameliorates the clinical and pathological course of murine myocarditis. J Clin Invest 1993; 90: 2022-2030
99. Szabó C, Mitchell JA, Gross SS. Thiemermann C, Vane JR: Nifedipine inhibits the induction of nitric oxide synthase by bacterial lipopolysaccharide. J Pharmacol Exp Ther 1993; 265: 674-680
100. Szabó C, Thiemermann C, Vane JR: Dihydropyridine antagonists and agonists of calcium channels inhibit the induction of nitric oxide synthase by endotoxin in cultured macrophages. Biochem Biophys Res Commun 1993; 196: 825-830
101. Mahe Y, Wakasugi H, Scamps C, Chouaib S, Tursz T: Role of calcium on interleukin-1 production by monocytes: its relevance during T cell proliferation. Lymphokine Cytokine Res 1991; 10: 165-172
102. Nathan C: Nitric oxide as a secretory product of mammalian cells. FASEB J 1992; 6: 3051-3064
103. Beckman JS: The double-edged role of nitric oxide in brain function and superoxide-mediated injury. J Dev Physiol 1991;15:53-59
104. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA: Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990; 87: 1620-1624